March 22nd 2024
In an interview with Targeted Oncology, Julie Chang, MD, discussed the minimal residual disease-adapted study in patients with previously untreated mantle cell lymphoma and the key findings from the trial.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Head-To-Head Phase 3 Trial To Evaluate BTK Inhibitors in MCL
August 17th 2021Inhibition of the Bruton’s tyrosine kinase (BTK) has shown potency in B-cell malignancies, leading to the exploration of treatment with the BTK inhibitor LOXO-305 in patients with mantle cell lymphoma (MCL) in the phase 3 BRUIN clinical trial.
Read More
Exploring a Time-to-Relapse Analysis for Rituximab and Transplant in MCL
July 24th 2021Peter A. Riedell, MD, discusses the clinical implication of using frontline high-dose rituximab-based therapy and autologous hematopoietic cell transplantation in patients with mantle cell lymphoma in an analysis of time to relapse.
Watch
Real-World Treatment Patterns and Outcomes in MCL Contrast With Clinical Trials
July 12th 2021In an interview with Targeted Oncology, Peter Martin, MD, discussed the real-world findings and how future agents should be developed to ensure optimal benefit for all patients with mantle cell lymphoma.
Read More
Rituximab Maintenance Improves Time-to-Next Treatment and OS in Patients With Mantle Cell Lymphoma
June 14th 2021Time-to-next treatment and overall survival were improved in a real-world study evaluating patients who received rituximab maintenance after first-line treatment with bendamustine and rituximab or R-CHOP in patients with mantle cell lymphoma, according to a retrospective analysis presented at the European Hematology Association 2021 Virtual conference.
Read More
Tazemetostat Elicits Preclinical Anti-Tumor Responses in MCL Cell Lines With BTK Resistance
May 26th 2021Mantle cell lymphoma cell lines with intrinsic resistance to BTK inhibitors displayed anti-tumor activity on treatment with tazemetostat as monotherapy or in combination with zanubrutinib, according to data from a preclinical analysis.
Read More
Ibrutinib or R-BAC Prolong PFS2 in Relapsed/Refractory Mantle Cell Lymphoma
May 5th 2021Patients with mantle cell lymphoma treated with second-line ibrutinib or the R-BAC regimen experienced improvement in progression-free survival 2 compared with treatment on rituximab and bendamustine and other regimens, according to findings from the international, retrospective MANTLE-FIRST study.
Read More
Preclinical Research Shows Potential for EZH1/2 Dual Inhibitor In Relapsed/Refractory MCL
April 19th 2021A new report on ibrutinib-resistant mantle cell lymphoma patient-derived xenograft mouse models shows the potential benefit of the EZH1/2 inhibitor OR-S1, as other similar inhibitors have shown benefit in patients with hematologic cancers.
Read More
Further Promise for CAR T-cell Therapy Use in R/R MCL Observed with Liso-Cel
March 24th 2021In an interview with Targeted Oncology, Maria Lia Palomba, MD, a hematologic oncologist at Memorial Sloan Kettering Cancer Center, discussed the efficacy and safety of liso-cel in patients with R/R MCL as observed in the phase 1 TRANSCEND NHL 001 study.
Read More
The Efficacy of Ibrutinib Plus Venetoclax for the Treatment of R/R MCL
February 18th 2021Constantine Tam, MD, discuses the outcomes of the phase 3 Sympatico Study, which evaluated the safety and efficacy of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for the treatment of relapsed or refractory mantle cell lymphoma compared to monotherapy.
Watch
KTE-X19 Continues to Show Durable Efficacy in Relapsed/Refractory MCL
February 12th 2021After a minimum of 1 year of follow-up, patients with relapsed/refractory mantle cell lymphoma demonstrated substantial and durable clinical benefit and a manageable safety profile when receiving KTE-X19 chimeric antigen receptor T cell therapy.
Read More
New Chemotherapy-Free Option May Be Identified for Elderly Patients With MCL
February 5th 2021In an interview with Targeted Oncology, Preetesh Jain, MBBS, MD, DM, PhD, assistant professor, reviewed the results seen with ibrutinib added to rituximab in older patients with mantle cell lymphoma and provided insight on how to manage the interesting toxicity profile observed with the combination.
Read More
Less Aggressive Treatment Warranted for MCL With Primary GI Involvement
January 27th 2021Patients with mantle cell lymphoma and primary gastrointestinal involvement have similar outcomes to those with secondary gastrointestinal involvement, according to results from one of the largest known studies of gastrointestinal mantle cell lymphoma.
Read More